Kent C. Shih

Learn More
Introduction The PI3 kinase (PI3K) pathway is a commonly dysregulated pathway in cancers and is an attractive target for antitumor therapy. BEZ235 is a potent, highly specific and selective dual PI3K/mTOR inhibitor. Methods Patients were enrolled in a 3 + 3 dose escalation design to determine the maximum tolerated dose (MTD), toxicities, and(More)
PURPOSE To evaluate the efficacy of adding bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, and everolimus, a mammalian target of rapamycin (mTOR inhibitor), to standard radiation therapy/temozolomide in the first-line treatment of patients with glioblastoma. PATIENTS AND METHODS Following surgical resection or biopsy, patients with(More)
BACKGROUND The mammalian target of rapamycin (mTOR) pathway is essential for tumor development, yet mTOR inhibitors have yielded modest results. This phase 1 study investigated the mTORC1/mTORC2 inhibitor CC-223 in patients with advanced cancer. METHODS Patients with advanced solid tumors or multiple myeloma received an initial dose of 7.5-60 mg of(More)
Immune responses are tightly regulated via signaling through numerous co-stimulatory and co-inhibitory molecules. Exploitation of these immune checkpoint pathways is one of the mechanisms by which tumors evade and/or escape the immune system. A growing understanding of the biology of immune checkpoints and tumor immunology has led to the development of(More)
BACKGROUND Merkel cell carcinoma is a rare, aggressive skin cancer with poor prognosis in patients with advanced disease. Current standard care uses various cytotoxic chemotherapy regimens, but responses are seldom durable. Tumour oncogenesis is linked to Merkel cell polyomavirus integration and ultraviolet-radiation-induced mutations, providing rationale(More)
This phase II trial examined the efficacy and toxicity of first-line treatment with everolimus, paclitaxel, and carboplatin in patients with advanced melanoma. Seventy patients with metastatic or locally advanced unresectable melanoma who had been untreated previously with chemotherapy or targeted agents received first-line treatment with everolimus (5 mg,(More)
Case Report A 21-year-old man presented to our clinic in June 2012 after being diagnosed with a recurrent ganglioglioma (GG) in the left temporal lobe and posterior brainstem. His original diagnosis was made at Kosair Children’s Hospital (Louisville, KY) in 1996 when he presented with headaches and neck pain. At that time, a magnetic resonance imaging (MRI)(More)
PURPOSE To evaluate efficacy and safety of bevacizumab, pertuzumab, and octreotide depot for advanced neuroendocrine tumors. METHODS Patients received bevacizumab 15 mg/kg and pertuzumab 420 mg IV q21 days with octreotide depot 30 mg IM q28 days. RESULTS Toxicities in 43 patients included diarrhea (63%), fatigue (63%), hypertension (44%), and nausea(More)
Meningiomas that progress after standard therapies are challenging with limited effective chemotherapy options. This phase II trial evaluated the efficacy of everolimus plus bevacizumab in patients with recurrent, progressive meningioma after treatment with surgical resection and local radiotherapy when appropriate. Patients with recurrent meningioma (WHO(More)
1116 Background: Anthracyclines demonstrate significant activity in breast cancer; however, cumulative cardiotoxicity limits their use. Amrubicin is a novel anthracycline with broad-spectrum antitumor activity and low potential for cardiotoxicity. We initiated a phase I/II trial of amrubicin in patients with MBC. Results from the phase I portion are(More)